The abstract is read at the publisher; the summary is JClub's.
NCI’s phased assay development awards (R21/R33 and UH2/UH3) support academic labs in turning unvalidated biomarker prototypes into robust LDTs and potentially FDA-approved IVDs.
- Why it matters: Biomarker assays often stall between early prototypes and clinically validated diagnostics, limiting reliable cancer diagnosis and trial matching.
- What they did: The program funds milestone-driven phases: analytical validation first, then clinical validation using well-annotated human biospecimens from existing studies or trials to link biomarkers to clinical endpoints.
- The result: By enabling commercial partnerships, larger clinical trials, and approved IVDs, the approach also supports LDTs for rare cancers and improves clinical trial screening and adoption of new detection technologies.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.